Monitoring the biological activity of abdominal aortic aneurysms beyond Ultrasound

Heart

Volumn 102, Issue 11, 2016, Pages 817-824

  Forsythe, Rachael O ^a   Newby, David E ^a   Robson, Jennifer M J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3 FLUORO 2 [4 [(2 NITRO 1H IMIDAZOL 1 YL)METHYL] 1H 1,2,3, TRIAZOL 1 YL] PROPAN 1 OL F 18; FLUCICLATIDE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROMETHYLCHOLINE F 18; GADOLINIUM; GE 180; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 6; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; NEUTROPHIL COLLAGENASE; RADIOPHARMACEUTICAL AGENT; SODIUM FLUORIDE F 18; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; [1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N' TETRAACETIC ACID] DEXTRO PHENYLALANINE 1, TYROSINE 3 OCTREOTATE GA 68; BIOLOGICAL MARKER;

ABDOMINAL AORTA ANEURYSM; AGE DISTRIBUTION; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE COURSE; ECHOGRAPHY; EXTRACELLULAR MATRIX; HUMAN; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SIGNAL NOISE RATIO; SMOKING HABIT; ABDOMINAL AORTA; ANIMAL; AORTIC ANEURYSM, ABDOMINAL; AORTOGRAPHY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIAGNOSTIC IMAGING; LESIONS AND DEFECTS; MACROPHAGE; MAGNETIC RESONANCE ANGIOGRAPHY; METABOLISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS;

ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; AORTOGRAPHY; BIOMARKERS; COMPUTED TOMOGRAPHY ANGIOGRAPHY; DILATATION, PATHOLOGIC; DISEASE PROGRESSION; HUMANS; MACROPHAGES; MAGNETIC RESONANCE ANGIOGRAPHY; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; ULTRASONOGRAPHY;

EID: 84959387216     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-308779     Document Type: Review

References (50)

1. Ashton HA, Buxton MJ, Day NE, et al, Multicentre Aneurysm Screening Study Group. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: A randomised controlled trial". Lancet 2002;360:1531-9.
2. The United Kingdom EVAR Trial Investigators. Endovascular versus open repair of abdominal aortic aneurysm. N Eng J Med 2010;362:1863-71.
3. Nicholls SC, Gardner JB, Meissner MH, et al. Rupture in small abdominal aortic aneurysms. J Vasc Surg 1998;28:884-8.
4. Mofidi R, Goldie VJ, Kelman J, et al. Influence of sex on expansion rate of abdominal aortic aneurysms. Br J Surg 2007;94:310-14.
5. Katz DJ, Stanley JC, Zelenock GB. Gender differences in abdominal aortic aneurysm prevalence, treatment, and outcome. J Vasc Surg 1997;25:561-8.
6. Golledge J, Muller J, Daugherty A, et al. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006;26:2605-13.
7. Brady AR, Thompson SG, Fowkes FGR, et al. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 2004;110:16-21.
8. De Rango P, Farchioni L, Fiorucci B, et al. Diabetes and Abdominal Aortic Aneurysms. Eur J Vasc Endovasc Surg 2014;47:243-61.
9. Golledge J, Karan M, Moran CS, et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes May be related to aberrant monocyte-matrix interactions. Eur Heart J 2008;29:665-72.
10. Torsney E, Pirianov G, Cockerill GW. Diabetes as a negative risk factor for abdominal aortic aneurysm-does the disease aetiology or the treatment provide the mechanism of protection? Curr Vasc Pharmacol 2013;11:293-8.
11. Larsson E, Granath F, Swedenborg J, et al. A population-based case-control study of the familial risk of abdominal aortic aneurysm. J Vasc Surg 2009;49:47-50; discussion 51.
12. Kurvers H, Veith FJ, Lipsitz EC, et al. Discontinuous, staccato growth of abdominal aortic aneurysms. J Am Coll Surg 2004;199:709-15.
13. Fillinger MF, Racusin J, Baker RK, et al. Anatomic characteristics of ruptured abdominal aortic aneurysm on conventional CT scans: implications for rupture risk. J Vasc Surg 2004;39:1243-52.
14. Hinchliffe RJ, Alric P, Rose D, et al. Comparison of morphologic features of intact and ruptured aneurysms of infrarenal abdominal aorta. J Vasc Surg 2003;38:88-92.
15. Vorp DA, Lee PC, Wang D, et al. Association of intraluminal thrombus in abdominal aortic aneurysm with local hypoxia and wall weakening. J Vasc Surg 2001;34:291-9.
16. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part II. Circulation 2003;108:1772-8.
17. Thompson MM, Jones L, Nasim A, et al. Angiogenesis in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1996;11:464-9.
18. Vallabhaneni SR, Gilling-Smith GL, How TV, et al. Heterogeneity of tensile strength and matrix metalloproteinase activity in the wall of abdominal aortic aneurysms. J Endovasc Ther 2004;11:494-502.
19. Wilson WRW, Anderton M, Schwalbe EC, et al. Matrix metalloproteinase-8 and-9 are increased at the site of abdominal aortic aneurysm rupture. Circulation 2006;113:438-45.
20. Jaffer FA, Weissleder R. Molecular Imaging in the Clinical Arena. JAMA 2005;293:855-62.
21. Adamson PD, Dweck MR, Newby DE. The vulnerable atherosclerotic plaque: in vivo identification and potential therapeutic avenues. Heart 2015;101:1755-66.
22. Kramer CM, Cerilli LA, Hagspiel K, et al. Magnetic resonance imaging identifies the fibrous cap in atherosclerotic abdominal aortic aneurysm. Circulation 2004;109:1016-21.
23. Richards JMJ, Semple SI, MacGillivray TJ, et al. Abdominal aortic aneurysm growth predicted by uptake of ultrasmall superparamagnetic particles of iron oxide: A pilot study. Circ Cardiovasc Imaging 2011;4:274-81.
24. Alam S, Spath N, Richards J, et al. Nanoparticle enhanced MRI: A novel method of investigating myocardial infarction. JACC 2013;61(10-S):E1072.
25. Tang TY, Howarth SPS, Miller SR, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009;53:2039-50.
26. McBride OMB, Berry C, Burns P, et al. MRI using ultrasmall superparamagnetic particles of iron oxide in patients under surveillance for abdominal aortic aneurysms to predict rupture or surgical repair: MRI for abdominal aortic aneurysms to predict rupture or surgery-the MA3RS study. Open Heart 2015;2:e000190.
27. Tarkin JM, Joshi FR, Rudd JHF. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol 2014;11:443-57.
28. Courtois A, Nusgens BV, Hustinx R, et al. 18F-FDG Uptake Assessed by PET/CT in abdominal aortic aneurysms is associated with cellular and molecular alterations prefacing wall deterioration and rupture. J Nuc Med 2013;54:1740-7.
29. Reeps C, Essler M, Pelisek J, et al. Increased 18F-fluorodeoxyglucose uptake in abdominal aortic aneurysms in positron emission/computed tomography is associated with inflammation, aortic wall instability, and acute symptoms. J Vasc Surg 2008;48:417-23; discussion 424.
30. Nchimi A, Cheramy-Bien JP, Gasser TC, et al. Multifactorial relationship between 18F-fluoro-deoxy-glucose positron emission tomography signaling and biomechanical properties in unruptured aortic aneurysms. Circ Cardiovasc Imaging 2014;7:82-91.
31. Barwick TD, Lyons OTA, Mikhaeel NG, et al. 18F-FDG PET-CT uptake is a feature of both normal diameter and aneurysmal aortic wall and is not related to aneurysm size. Eur J Nuc Med Mol Imaging 2014;41:2310-18.
32. Kotze CW, Groves AM, Menezes LJ, et al. What is the relationship between 18F-FDG aortic aneurysm uptake on PET/CT and future growth rate? Eur J Nuc Med Mol Imaging 2011;38:1493-9.
33. Folco EJ, Sheikine Y, Rocha VZ, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages: implications for imaging atherosclerosis with fluorine-labeled 2-Deoxy-D-glucose positron emission tomography. J Am Coll Cardiol 2011;58:603-14.
34. Rinne P, Hellberg S, Kiugel M, et al. Comparison of Somatostatin Receptor 2-Targeting PET Tracers in the Detection of Mouse Atherosclerotic Plaques. Mol Imaging Biol 2016;18:99-108.
35. Li X, Samnick S, Lapa C, et al. 68Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with18F-FDG, calcium burden and risk factors. EJNMMI Res 2012;2:52.
36. Gaemperli O, Shalhoub J, Owen DRJ, et al. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur Heart J 2012;33:1902-10.
37. Matter CM, Wyss MT, Meier P, et al. F-Choline Images Murine Atherosclerotic Plaques Ex Vivo. Arterioscler Thromb Vasc Biol 2006;26:584-9.
38. Bucerius J, Schmaljohann J, Bohm I, et al. Feasibility of 18-F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans-first results. Eur J Nuc Med Mol Imaging 2008;35:815-20.
39. Sarda-Mantel L, Alsac JM, Boisgard R, et al. Comparison of 18F-fluoro-deoxy-glucose, 18F-fluoro-methyl-choline, and 18F-DPA714 for positron-emission tomography imaging of leukocyte accumulation in the aortic wall of experimental abdominal aneurysms. J Vasc Surg 2012;56: 765-73.
40. Aikawa E, Nahrendorf M, Figueiredo JL, et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 2007;116:2841-50.
41. Rudd JHF, Myers KS, Bansilal S, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2009;2:107-15.
42. Duer MJ, Friscić T, Proudfoot D, et al. Mineral surface in calcified plaque is like that of bone: further evidence for regulated mineralization. Arterioscler Thromb Vasc Biol 2008;28:2030-4.
43. Buijs RVC, Willems TP, Tio RA, et al. Calcification as a Risk Factor for Rupture of Abdominal Aortic Aneurysm. EurJ Vasc Endovasc Surg 2013;46: 542-8.
44. Reeps C, Maier A, Pelisek J, et al. Measuring and modeling patient-specific distributions of material properties in abdominal aortic aneurysm wall. Biomech Model Mechanobiol 2013;12:717-33.
45. Kelly-Arnold A, Maldonado N, Laudier D, et al. Revised microcalcification hypothesis for fibrous cap rupture in human coronary arteries. Proc Natl Acad Sci USA 2013;110:10741-6.
46. Joshi NV, Vesey AT, Williams MC, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: A prospective clinical trial. Lancet 2014;383:705-13.
47. Tegler G, Estrada S, Hall H, et al. Autoradiography screening of potential positron emission tomography tracers for asymptomatic abdominal aortic aneurysms. Ups J Med Sci 2014;119:229-35.
48. van der Valk FM, Sluimer JC, Vöö SA, et al. In Vivo Imaging of Hypoxia in Atherosclerotic Plaques in Humans. JACC Cardiovasc Imaging 2015;8: 1340-1.
49. Lacerda S, Andia ME, Botnar R. Development of a tropoelastin-binding MR contrast agent for in vivo imaging of impaired elastogenesis in atherosclerosis. J Cardiovasc Magn Reson 2015;17(Suppl 1):O102.
50. Protti A, Lavin B, Dong X, et al. Assessment of Myocardial Remodeling Using an Elastin/Tropoelastin Specific Agent with High Field Magnetic Resonance Imaging (MRI). J Am Heart Assoc 2015;4:e001851.